ENTRY       D10549                      Drug
NAME        Cabotegravir sodium (JAN/USAN);
            Vocabria (TN)
PRODUCT     VOCABRIA (ViiV Healthcare Company)
FORMULA     C19H16F2N3O5. Na
EXACT_MASS  427.0956
MOL_WEIGHT  427.334
CLASS       Antiviral
             DG03107  Anti-HIV agent
              DG03135  HIV integrase inhibitor
            Metabolizing enzyme substrate
             DG02924  UGT substrate
              DG03183  UGT1A1 substrate
              DG03188  UGT1A9 substrate
REMARK      Therapeutic category: 6250
            ATC code: J05AJ04
            Chemical structure group: DG01628
            Product (DG01628): D10548<JP/US> D10549<JP/US>
            Product (mixture): D11966<US>
EFFICACY    Antiviral, HIV integrase inhibitor
  DISEASE   HIV-1 infection [DS:H01563]
TARGET      HIV-1 integrase [KO:K24803]
  PATHWAY   ko03230(K24803)  Viral genome structure
            ko03240(K24803)  Viral replication
            ko03250(K24803)  Viral life cycle - HIV-1
METABOLISM  Enzyme: UGT1A1 [HSA:54658]; UGT1A9 [HSA:54600]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J05 ANTIVIRALS FOR SYSTEMIC USE
               J05A DIRECT ACTING ANTIVIRALS
                J05AJ Integrase inhibitors
                 J05AJ04 Cabotegravir
                  D10549  Cabotegravir sodium (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antivirals
              Anti-HIV Agents, Integrase Inhibitors (INSTI)
               Cabotegravir
                D10549  Cabotegravir sodium (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              62  Chemotherapeutics
               625  Antivirals
                6250  Antivirals
                 D10549  Cabotegravir sodium (JAN/USAN)
            Drug groups [BR:br08330]
             Antiviral
              DG03107  Anti-HIV agent
               DG03135  HIV integrase inhibitor
                DG01628  Cabotegravir
                 D10549  Cabotegravir sodium
             Metabolizing enzyme substrate
              DG02924  UGT substrate
               DG03183  UGT1A1 substrate
                DG01628  Cabotegravir
                 D10549  Cabotegravir sodium
               DG03188  UGT1A9 substrate
                DG01628  Cabotegravir
                 D10549  Cabotegravir sodium
            Drug classes [BR:br08332]
             Antiviral
              DG03107  Anti-HIV agent
               D10549  Cabotegravir sodium
            Antimicrobials [BR:br08307]
             Antivirals
              Genome replication inhibitor
               HIV integrase inhibitor
                D10549  Cabotegravir sodium (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10549
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10549
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10549
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10549
            Drug groups [BR:br08330]
             Antiviral
              DG03107  Anti-HIV agent
               DG03135  HIV integrase inhibitor
                DG01628  Cabotegravir
             Metabolizing enzyme substrate
              DG02924  UGT substrate
               DG03183  UGT1A1 substrate
                DG01628  Cabotegravir
               DG03188  UGT1A9 substrate
                DG01628  Cabotegravir
DBLINKS     CAS: 1051375-13-3
            PubChem: 254741511
            ChEBI: 172948
ATOM        30
            1   C8y C    17.9200  -17.4300
            2   N4y N    17.9200  -16.0300
            3   C8x C    19.1100  -15.3300
            4   C8y C    20.3700  -16.0300
            5   C8y C    20.3700  -17.4300
            6   C8y C    19.1100  -18.1300
            7   C5x C    16.7300  -18.1300
            8   N1y N    15.4700  -17.4300
            9   C1y C    15.4700  -16.0300
            10  C1x C    16.7300  -15.3300
            11  O5x O    16.7300  -19.5300
            12  O1a O    19.1100  -19.5300 #-
            13  O5x O    21.5600  -18.1300
            14  C5a C    21.5600  -15.3300
            15  N1b N    22.7500  -16.0300
            16  O5a O    21.5600  -13.9300
            17  C1b C    23.9400  -15.3300
            18  C8y C    25.1300  -16.0300
            19  C8x C    26.3200  -15.3300
            20  C8x C    27.5800  -16.0300
            21  C8y C    27.5800  -17.4300
            22  C8x C    26.3900  -18.1300
            23  C8y C    25.1300  -17.4300
            24  X   F    23.9400  -18.1300
            25  X   F    28.7700  -18.1300
            26  O2x O    14.1400  -15.6100
            27  C1x C    13.3000  -16.7300
            28  C1y C    14.1400  -17.8500
            29  C1a C    13.7200  -19.1800
            30  Z   Na   21.7000  -20.8600 #+
BOND        32
            1     1   2 1
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 1
            6     1   6 2
            7     1   7 1
            8     7   8 1
            9     8   9 1
            10    9  10 1
            11    2  10 1
            12    7  11 2
            13    6  12 1
            14    5  13 2
            15    4  14 1
            16   14  15 1
            17   14  16 2
            18   15  17 1
            19   17  18 1
            20   18  19 2
            21   19  20 1
            22   20  21 2
            23   21  22 1
            24   22  23 2
            25   18  23 1
            26   23  24 1
            27   21  25 1
            28    9  26 1
            29   26  27 1
            30   27  28 1
            31    8  28 1
            32   28  29 1 #Up
///
